Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $40,241 | 2,212 | 97.2% |
| Education | $935.78 | 26 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $222.12 | 13 | 0.5% |
| Entertainment | $9.11 | 1 | 0.0% |
| Gift | $0.03 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,629 | 202 | $0 (2024) |
| UCB, Inc. | $3,581 | 219 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $2,578 | 106 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $2,143 | 83 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,483 | 115 | $0 (2024) |
| Biogen, Inc. | $1,470 | 90 | $0 (2024) |
| Allergan, Inc. | $1,430 | 122 | $0 (2022) |
| Kyowa Kirin, Inc. | $1,384 | 59 | $0 (2024) |
| Eisai Inc. | $1,319 | 98 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,290 | 64 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,739 | 399 | ABBVIE INC. ($1,399) |
| 2023 | $7,160 | 375 | AbbVie Inc. ($1,119) |
| 2022 | $6,589 | 375 | ABBVIE INC. ($614.34) |
| 2021 | $5,978 | 338 | Novartis Pharmaceuticals Corporation ($500.46) |
| 2020 | $3,046 | 178 | Allergan, Inc. ($446.19) |
| 2019 | $4,102 | 242 | UCB, Inc. ($565.71) |
| 2018 | $2,719 | 176 | UCB, Inc. ($348.71) |
| 2017 | $3,076 | 172 | UCB, Inc. ($362.92) |
All Payment Transactions
2,255 individual payment records from CMS Open Payments — Page 2 of 91
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Neuroscience | ||||||
| 11/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: Neuropsychiatry | ||||||
| 11/18/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/14/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $27.57 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $3.03 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: NEUROLOGY | ||||||
| 11/07/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $24.53 | General |
| Category: NEUROLOGY | ||||||
| 11/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $26.47 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: NEUROLOGY | ||||||
| 11/06/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $10.90 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: AMANTADINE | ||||||
| 10/30/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: PAIN | ||||||
| 10/30/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $2.86 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.35 | General |
| Category: PSYCHIATRY | ||||||
| 10/28/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.14 | General |
| 10/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Neuropsychiatry | ||||||
| 10/28/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Neurology | ||||||
| 10/24/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $24.34 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.57 | General |
| Category: Neuroscience | ||||||
| 10/23/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Immunology | ||||||
| 10/22/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: Neurology | ||||||
| 10/22/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 3,308 | 80,519 | $2.5M | $1.1M |
| 2022 | 23 | 2,658 | 72,839 | $2.1M | $918,398 |
| 2021 | 24 | 2,729 | 72,571 | $2.1M | $939,435 |
| 2020 | 22 | 2,203 | 53,211 | $1.6M | $646,306 |
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 138 | 70,091 | $560,720 | $346,902 | 61.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 678 | 1,747 | $330,183 | $143,380 | 43.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 396 | 1,264 | $252,800 | $115,217 | 45.6% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 191 | 204 | $152,796 | $74,582 | 48.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 325 | 325 | $130,000 | $59,553 | 45.8% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 211 | 211 | $200,450 | $55,685 | 27.8% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 111 | 296 | $140,600 | $47,217 | 33.6% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2023 | 64 | 1,975 | $187,625 | $42,653 | 22.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 217 | 218 | $81,750 | $22,790 | 27.9% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 26 | 49 | $36,750 | $20,832 | 56.7% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 101 | 102 | $81,090 | $19,961 | 24.6% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 109 | 110 | $63,250 | $17,718 | 28.0% |
| 97530 | Therapy procedure using functional activities | Office | 2023 | 12 | 525 | $51,450 | $14,438 | 28.1% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 48 | 48 | $14,400 | $11,290 | 78.4% |
| 92546 | Test for abnormal eye movement using a rotating chair | Office | 2023 | 86 | 87 | $17,400 | $10,589 | 60.9% |
| 64520 | Injection of anesthetic agent into middle or lower spine sympathetic nerve | Office | 2023 | 31 | 41 | $13,325 | $8,890 | 66.7% |
| 92540 | Evaluation and testing for balance with recording | Office | 2023 | 86 | 87 | $19,500 | $8,663 | 44.4% |
| 97112 | Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | Office | 2023 | 17 | 277 | $26,315 | $7,195 | 27.3% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 16 | 45 | $13,500 | $6,043 | 44.8% |
| 97162 | Evaluation for physical therapy, typically 30 minutes | Office | 2023 | 59 | 60 | $7,500 | $5,460 | 72.8% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 14 | 14 | $6,650 | $3,624 | 54.5% |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 2023 | 38 | 368 | $34,960 | $3,091 | 8.8% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 17 | 38 | $9,500 | $2,761 | 29.1% |
| 92537 | Test to assess balance during warm and cool irrigation in both ears | Office | 2023 | 69 | 70 | $10,500 | $2,572 | 24.5% |
| G0425 | Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | Office | 2023 | 26 | 29 | $5,481 | $2,489 | 45.4% |
About Dr. Michael Amoashiy, MD
Dr. Michael Amoashiy, MD is a Specialist healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346354982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Amoashiy, MD has received a total of $41,408 in payments from pharmaceutical and medical device companies, with $8,739 received in 2024. These payments were reported across 2,255 transactions from 87 companies. The most common payment nature is "Food and Beverage" ($40,241).
As a Medicare-enrolled provider, Amoashiy has provided services to 10,898 Medicare beneficiaries, totaling 279,140 services with total Medicare billing of $3.6M. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Other Specialties Neuroradiology, Neurology
- Location Brooklyn, NY
- Active Since 08/19/2006
- Last Updated 07/12/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346354982
Products in Payments
- BOTOX (Biological) $1,739
- INGREZZA (Drug) $1,723
- Briviact (Drug) $1,613
- VRAYLAR (Drug) $1,280
- REXULTI (Drug) $1,164
- Fycompa (Drug) $1,098
- AUSTEDO (Drug) $1,039
- CAPLYTA (Drug) $1,013
- QULIPTA (Drug) $1,007
- KESIMPTA (Drug) $968.08
- Neupro (Drug) $926.61
- NUPLAZID (Drug) $918.41
- Aimovig (Biological) $896.67
- UBRELVY (Drug) $879.79
- TYSABRI (Biological) $758.08
- EMGALITY (Drug) $746.48
- Nourianz (Drug) $728.58
- NASCOBAL (Drug) $696.97
- Vimpat (Drug) $684.64
- NOURIANZ (Drug) $655.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Brooklyn
Idan Sharon, M.d, M.D
Specialist — Payments: $2.3M
Dr. Sean Studer, M.d, M.D
Specialist — Payments: $411,591
Dr. Michael Lewis, M.d, M.D
Specialist — Payments: $68,268
Dr. Marc Avram, Md, MD
Specialist — Payments: $48,018
Dr. Madhavi Reddy, M.d, M.D
Specialist — Payments: $40,649
Mr. Benjamin Wu
Specialist — Payments: $23,392